Clinical trial · Interventional
Effects of Reiki, Yoga, Meditation, on the Physical and Psychological Symptoms of Chemotherapy-Induced Peripheral Neuropathy
A Randomized, Four-Arm Study Comparing Reiki, Yoga, Meditation, or Patient Education Group for Addressing Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT01569269CI-TRIAL-00006654completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test whether people with symptoms of chemotherapy-induced peripheral neuropathy (CIPN) receive physical or psychological benefits from participating in a six-week Reiki, Yoga, Meditation, or Educational experience.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Holistic Education | Other | — | UNRESOLVED |
| Meditation Intervention | Behavioral | — | UNRESOLVED |
| Reiki | Behavioral | — | UNRESOLVED |
| Yoga Intervention | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Yoga
- description
- See intervention description
- interventionNames
- Behavioral: Yoga Intervention
- type
- EXPERIMENTAL
- label
- Meditation
- description
- See intervention description
- interventionNames
- Behavioral: Meditation Intervention
- type
- EXPERIMENTAL
- label
- Reiki
- description
- see intervention description
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * participants must be of at least 18 years of age, * participants must have persistent symptoms of CIPN resulting from treatment with vinca alkaloid, taxane, platinum class chemotherapies or immunomodulators (Thalidomide) or antineoplastic agents (Velcade) for a known cancer diagnosis * participants must have completed chemotherapy at least three months prior to beginning the study, * participants cannot concurrently receive chemotherapy treatment for cancer, nor * actively take part in one of the complementary modalities offered in this pilot study. * participants will be required to have an ability to comfortably speak, read, and understand English. * participants must be fully oriented and possess the capacity to understand and provide informed consent for participation in the study. Exclusion Criteria: * failure to meet any one of the inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.